Professional
Added to YB: 2024-09-10
Pitch date: 2024-06-30
TEVA [neutral]
Teva Pharmaceutical Industries Limited
+81.98%
current return
Author Info
No bio for this author
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$30.7B
Pitch Price
$16.37
Price Target
N/A
Dividend
N/A
EV/EBITDA
9.65
P/E
43.30
EV/Sales
2.72
Sector
Pharmaceuticals
Category
value
RS Large Cap Val Strategy Portfolio Holding: Teva Pharmaceutical Industries Limited
TEVA: Outperformed peers in Q2 on positive clinical data, new product launches, stable generic pricing. Strong sales of Ajovy & Austedo. Phase 3 Olanzapine success, Humira/Stelara biosimilars approved. Net leverage down to ~3x. Undervalued at 7x EV/EBITDA despite transformation from commodity generics.
Read full article (1 min)